



# 7<sup>th</sup> EUROPEAN COURSE ON PHARMACOKINETICS AND PHARMACODYNAMICS OF PROTEIN THERAPEUTICS

PRINCIPLES AND PHARMACOMETRIC APPROACHES & INTRODUCTION TO SIMULATIONS WITH E-CAMPSIS

BARCELONA, SPAIN, SEPTEMBER 15-18, 2026

## COURSE DIRECTORS

Bernd Meibohm, University of Tennessee, and Johan Gabrielsson, MedDoor AB, Gothenburg

## ORGANIZERS AND REGISTRATION SUPPORT

Calvagone SAS, France

## LOCAL HOSTS

Andreas Lindauer (Scientific Director, Calvagone)

This 4-day course will introduce participants to basic principles in the pharmacokinetics and pharmacodynamics of novel therapeutic proteins and provide opportunities for basic hands-on exercises in the PK/PD evaluation of these compounds. Topics include target-mediated drug disposition, tissue and tumor penetration, first-in-human dose selection, immunogenicity, clinical pharmacology challenges, biosimilars, ADCs, bispecific antibodies and drug-drug interactions.

The course is a shortened version of the week-long course on 'Pharmacokinetics and Pharmacodynamics of Protein Therapeutics - Concepts and Hands-On Modeling and Simulation' that Profs Meibohm and Gabrielsson have offered for the last fifteen years in the United States.

On the 4<sup>th</sup> day, Calvagone will give a hands-on introduction to e-Campsis®, the online PK/PD simulator, with examples focused on protein PK.

Further information on e-Campsis can be found at [www.e-campsis.com](http://www.e-campsis.com)



## COURSE LOGISTICS

### COURSE VENUE

TBD

### REGISTRATION FEE

Regular: **€2200**      Academia/Trainee: **€800**


**Early-bird registration (before May 31st 2026): 10% discount**

Registration fee includes access to all course sessions, course material in electronic form, 3 months free access to e-Campsis® pro, lunch and coffee breaks, and a joint dinner.

The number of course participants will be limited to 30. The number of slots for academic participants and trainees will also be limited.

For registration scan the QR code or go to:

<https://forms.office.com/e/SVKhAs7zY0rm>



## ACCOMMODATION

Participants are free to enjoy the wide offer of hotels in Barcelona at walking distance or easily accessible by local transportation through the usual booking sites. Participants need to make their own hotel arrangements.

## TRAVEL INFORMATION

Barcelona is well-connected by air, with most European cities offering direct flights. The venue is approximately 30 minutes away by taxi. Alternatively, going by the Airport Shuttle Bus takes about 1 hour.

## CONTACT DETAILS OF THE ORGANIZER

Email [contact@calvagone.com](mailto:contact@calvagone.com)  
Web <http://www.calvagone.com>

## CANCELLATION POLICY

### Cancellation by Participant

Cancellations made more than 30 days before the course start date are subject to a fee of €750 (industry) or €275 (academic). No refunds will be issued for cancellations made 30 days or less before the course. Registrations may be transferred to a colleague from the same organization at no additional cost.

### Cancellation or Rescheduling by the Organizer

The organizer reserves the right to cancel or reschedule the workshop due to insufficient enrolment, force majeure, or the unavailability of key instructors. Participants will be offered a place in the rescheduled workshop or, if rescheduling is not possible, a full refund of the registration fee.

Time	Day 1 (15/09/2026)	Day 2 (16/09/2026)	Day 3 (17/09/2026)	Day 4 (18/09/2026)
<b>Topic</b>	<b>Basic Concepts</b>	<b>PK/PD</b>	<b>Developmental Aspects</b>	<b>Simulations with e-Campsis</b>
09:00	Introduction (Bernd & Johan)	Recap and Outline of the Day (Bernd & Johan)	Recap and Outline of the Day (Bernd & Johan)	Outline of the Day
09:15	Basic Pharmacokinetics of Proteins (Bernd)	TMDD: Steady-state relationship of ligand, target and complex I (Johan)	Clinical Pharmacology Challenges for Protein Therapeutics (Bernd)	Introduction to the Campsis simulation suite
09:45	<i>Discussion</i>	<i>Discussion</i>	<i>Discussion</i>	
10:00	Drug Disposition of Monoclonal Antibodies (Bernd)	TMDD: Steady-state relationship of ligand, target and complex II (Johan)	Disease States & Covariates Modulating PKPD of Proteins (Bernd)	Hands-on: Simulating a simple PK model in e-Campsis
10:30	<i>Discussion</i>	<i>Discussion</i>	<i>Discussion</i>	
10:45	<b>Break</b>			
11:00	Basic Concepts of Target-Mediated Drug Disposition I (Johan)	Tissue Distribution and Tumor Penetration	PKPD and Clinical Pharmacology of Bispecific Antibody Derivatives (Bernd)	Hands-on: Simulating different scenarios, post-processing of results
11:30	<i>Discussion</i>	<i>Discussion</i>	<i>Discussion</i>	
11:45	Basic Concepts of Target-Mediated Drug Disposition II (Johan)	Challenges in the Development of Antibody-Drug Conjugates (Bernd)	New expressions of effect-duration, importance of free analytes (Johan)	Hands-on: Solve exercises of days 1 and 2 with e-Campsis
12:15	<i>Discussion</i>	<i>Discussion</i>	<i>Discussion</i>	
12:30	<b>Lunch</b>			
13:30	Extravascular Administration of Proteins (Bernd)	First-In-Human Dose Predictions (Bernd)	Evaluation of Drug-Drug Interactions of Therapeutic Proteins (Bernd)	continued
13:50	<i>Discussion</i>	<i>Discussion</i>	<i>Discussion</i>	
14:00	Presentation of feasibility exercise (Johan & Bernd)	Presentation of Practical Biologics Exercise (Johan & Bernd)	Immunogenicity: Impact on PK and PD (Bernd)	Hands-on: First-in-human dose prediction with a minimal PBPK-TMDD model
14:30	Hands-on exercise	Hands-on exercise	<i>Discussion</i>	
15:00	<b>Break</b>			
15:15	Discussion of feasibility exercise (Johan & Bernd)	Discussion of Practical Biologics Exercise (Johan & Bernd)	Pattern Recognition in PK and PD (Johan & Bernd)	Hands-on: Sensitivity analysis and other advanced features
16:00-16:15	Wrap-up (Johan & Bernd)	Wrap-up (Johan & Bernd)	Wrap-up (Johan & Bernd)	Final wrap-up and closing remarks

The schedule may be subject to minor changes.

